MyFinsight
Home
Blog
About
Contact
Download
Download image
Net increase
(decrease) in cash
-$954,560
Prepaid expenses
-$2,179,230
Amortization of right-of-use
assets
$35,041
Stock-based compensation
expense
$9,792
Accounts payable
$5,978
Accrued expenses
$1,325
Net cash used in
operating activities
-$954,560
Canceled cashflow
$2,231,366
Net loss for the
period
-$3,150,228
Lease liabilities
-$35,698
Back
Back
Cash Flow
source: myfinsight.com
Curanex Pharmaceuticals Inc (CURX)
Curanex Pharmaceuticals Inc (CURX)